SERA PROGNOSTICS, INC. Deferred Tax Assets, Operating Loss Carryforwards
SERA PROGNOSTICS, INC. (SERA) had Deferred Tax Assets, Operating Loss Carryforwards of $70.63 million as of 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-18
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $70.63M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $61.62M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $53.07M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $46.67M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $70.63M 10-K · filed 2026-03-18 |
| 2024-12-31 | $61.62M 10-K · filed 2026-03-18 |
| 2023-12-31 | $53.07M 10-K · filed 2025-03-19 |
| 2022-12-31 | $46.67M 10-K · filed 2024-03-20 |
| 2021-12-31 | $39.42M 10-K · filed 2023-03-22 |
| 2020-12-31 | $31.23M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |